The platform technology of Intralytix is based on using naturally occurring, non-genetically modified (non-GMO) lytic bacteriophages for developing "green" commercial products for a variety of applications.

[2] In 2018, Intralytix was granted the first FDA-approved IND for a double-blind, randomized, placebo-controlled clinical trial in the US for an orally administered phage preparation in patients with inactive Crohn's disease (NCT03808103).

In 2011, Intralytix received regulatory clearance from the FDA for its EcoShield food safety product effective against E. coli O157:H7 (FCN No.

Subsequent phage preparations received regulatory clearance from the FDA through Generally Recognized As Safe (GRAS) acknowledgments.

It has several all-natural, antibiotic-free phage-based products capable of treating human diseases of bacterial origin in various stages of development (preclinical through Phase 2a).

[11] The company is currently sponsoring a Phase 1/2a clinical trial (under an IND approval from the FDA) of the EcoActive phage preparation for targeting adherent-invasive E. coli associated with Crohn's disease (NCT03808103).

This trial is currently enrolling patients at the Icahn School of Medicine at the Mount Sinai Hospital in New York, NY and at the Johns Hopkins University in Baltimore, MD.

[13] Also in Q3 2023, the company plans to begin clinical trials of another human therapeutic product, VRELysin, to treat Vancomycin Resistant Enterococci (NCT05715619).

After application, the phages act to reduce the contamination of specific target bacteria, if present on the animal, and prevent it from entering the facility.